CWBHF - Charlotte's Web Holdings, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
17.00
-0.17 (-0.99%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close17.17
Open17.01
Bid0.00 x 0
Ask0.00 x 0
Day's Range16.37 - 17.44
52 Week Range8.13 - 25.25
Volume473,173
Avg. Volume625,101
Market Cap835.149M
Beta (3Y Monthly)N/A
PE Ratio (TTM)202.38
EPS (TTM)0.08
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est24.41
Trade prices are not sourced from all markets
  • Benzinga

    Charlotte's Web Holdings Obtains First US Patent Granted For Hemp Strain

    Charlotte's Web Holdings Inc (OTC: CWBHF ), the producer of the Charlotte’s Web brand of CBD products, secured the first U.S. patent for a strain of hemp in July, according to Leafly .   The company’s ...

  • Charlotte’s Web Holdings’ New Hemp Patent Could Be a Game Changer
    TipRanks

    Charlotte’s Web Holdings’ New Hemp Patent Could Be a Game Changer

    It was recently discovered that Charlotte's Web Holdings (CWBHF) has been awarded what appears to be the first U.S. patent for a hemp strain, according to US Patent and Trademark Office filings.A report from Leafly noted that the related "documents describe CW2A as a hardy plant, resistant to cold and capable of producing up to 6.24% CBD and only 0.27% THC."In the fast-growing CBD market, a patent like this could be a huge competitive advantage for Charlotte’s Web.The patent itselfThe first thing to understand about this patent is it's a plant patent, not what is identified as a utility patent. That means the patent held by Charlotte's Web gives it legal protection from a competitor growing that specific cultivar from a clone.Charlotte's Web may have also been awarded a Utility patent as well, but that isn't available to the public until after a waiting period of 18 months. The basic difference between the two is a Utility patent also covers seeds and the various chemical compositions of the plant. A Utility patent gives a plant a wider range of protections.As for the characteristics of the plant itself, it would yield a significant amount of dry weight CBD which would be then extracted and sold to consumers. It also appears to have the ability to be grown in a number of different environments, providing more flexibility on the production side of the equation.With a number of U.S. hemp farmers struggling at times to keep their hemp from getting hot, which means from exceeding the legal 0.3% THC threshold, the low amount of THC in CW2A would provide a wide margin of safety.Keep in mind that this is a hemp patent, not a cannabis patent. There have been a number of cannabis patents that have been applied for and approved of.The difference between hemp and cannabis isn't botanical, but legal. Hemp is identified legally as having no more than 0.3% THC in it.Significance of the patentI've been saying for some time the long-term profitability in the cannabis sector is going to eventually come to those companies that are able to develop various strains or research-backed characteristics that differentiate themselves from competitors.In the short term recreational pot will continue to be the biggest generator or revenue, but CBD and medical pot are eventually going to be the products that generate the widest margins and strongest earnings.As for this hemp patent and Charlotte's Web, this could be a huge competitive advantage for the company. It's interesting that the company didn't tout the patent, which suggests to me it either is waiting for a Utility patent to be revealed, or for those of us that discover it and report on its potential.With the well-known Charlotte's Web strain, and the Stanley brothers adding a hemp patent to their arsenal, it could be a tremendous branding and marketing opportunity for the company, which could be more important than the hemp patent and the accompanying positive characteristics.The Stanley brothers, the founders and operators of Charlotte's Web Holdings, are excellent at branding and marketing. It's easy to see how they could leverage this to take a commanding lead in the CBD market.That's why it's puzzling as to why they didn't go public with their achievement. It's also why I think there's more to come, by which I mean a potential Utility patent to be revealed.Now that the cat is out of the bag, I wouldn't be surprised to see some branding and marketing movement on this front.Whatever the timing ends up being, it's apparent the company has taken a lead on its competitors, and if consumers perceive the brand to be superior to other brands, it will be a moat that the company can defend; it would win a lot of market share in the current CBD commodity market.Consensus VerdictThe cannabis player stands as a 'Strong Buy' name among Wall Street analysts. In the last three months, Charlotte's Web has won three bullish recommendations. With a return potential of close to 40%, the stock's consensus price target lands at $23.17.ConclusionThere are several things to like about the hemp patent. It adds another arrow to the branding and marketing quiver of Charlotte's Web; provides a quality product that should result in higher extraction of CBD and the ability to grow under various conditions; and most importantly, should allow the company to leverage products derived from the strain to be differentiated from competitors.With the proven branding and marketing expertise of management, this could be a significant step into winning market share in the CBD market, which is projected to quickly grow into a double-figure multi-billion dollar market.This is going to be a big growth catalyst for the company if the traits listed in the hemp patent are proven to be consistently accurate, and consumers consider it to be a better product than other CBD offerings.This hot cannabis stock is also resonating with investors, with individual portfolios in the TipRanks database showing a net increase in Charlotte's Web.

  • Aurora vs Canopy vs Charlotte’s Web: Which Cannabis Stock Will Outperform the Rest?
    TipRanks

    Aurora vs Canopy vs Charlotte’s Web: Which Cannabis Stock Will Outperform the Rest?

    It’s clear that the seeds for future growth have been planted in a budding cannabis space. According to Grand View Research, the global legal marijuana market is expected to reach $66.3 billion by 2025, with many investors hoping to get in on the action. That being said, it hasn’t necessarily been smooth sailing for cannabis stocks this year. A few have actually seen growth slow with some being weighed down by tax concerns in the U.S. and supply-side issues. For example, Tilray (TLRY) has plummeted 61% year-to-date. With that in mind, analysts say that some cannabis stocks look more poised to soar than the rest. We wanted to take a closer look at 3 of the top players in this space to see which cannabis stock Wall Street analysts believe will come out on top. Let’s dig in. Aurora Cannabis Inc. (ACB)With shares falling 31% in the last three months, investors are wondering what is going with Aurora.The cannabis company still has a way to go before it sees a profit. While Aurora hasn’t posted results for fiscal Q4 2019 yet, it did report a CA$158.4 million loss in fiscal Q3. However, management pointed out that several positive initiatives have placed Aurora on the road towards profitability.The company has made substantial efforts to improve the scale of its business, with Aurora already leading the industry when it comes to production capacity. Currently, production is on track to reach 625,000 kilograms of cannabis per year. Aurora wants to improve this figure by bringing industrial scale to its growing facilities. Management hopes to accomplish this through the ramping up of its Sky and Sun locations. Not to mention these facilities could bring production costs down, with Sky’s production costs expected to be less than $1.00 per gram.The company will also start to develop new technology, genetics and intellectual property at two new test facilities in order to drive sustainable and high-quality outdoor production.Based on the reduction of its operating costs and improved product offerings from its superior facilities, Ladenburg Thalmann & Co. analyst Glenn Mattson believes Aurora has the advantage over its competitors. As a result, he initiated coverage with a Buy and set a $9 price target on July 17. The four-star analyst thinks share prices could surge 61% over the next twelve months.All in all, the Street is cautiously optimistic about ACB. It has a ‘Moderate Buy’ analyst consensus and a $9 average price target, suggesting 56% upside potential. Canopy Growth (CGC) The next cannabis stock on our list has also been the target of negative media sentiment after it reported a C$1.28 billion loss in its first fiscal quarter of 2020 as well as missed analyst estimates for revenue on August 15. That’s not to say that analysts have given up on Canopy, with some telling investors they will just have to be patient.It’s important to note that Canopy stands to benefit from the 2.0 market, or Canada’s plan to let cannabis producers add popular vapes, edibles and infused beverages to be sold legally later this year. “The Canadian space is about to gain a fair amount of pricing power, in our view, as the 2.0 market opens up late this year,” Seaport Global analyst Brett Hundley explained. The company has taken several steps forward in its journey towards profitability. In an effort to expand its 30% stake in the Canadian adult recreational cannabis market, Canopy has made a significant investment in production and retail. The analyst believes the strengthening of its brand leading up to the launch of its edibles in late-fall was an especially important step in the right direction. “We think Canopy can regain some lost share of shelf, as it leverages R&D, IP and partnerships to bring leading value-added products to market,” Hundley added.It doesn’t hurt that Canopy has placed a focus on growing its customer base outside of Canada. Over the last few years, new facilities have been built to enable production in Germany, Denmark and the U.S. Once they become fully operational, they are expected to drive significant revenue. All of these factors played into Hundley’s Canopy ratings boost. On August 26, the one-star analyst upgraded CGC from a Hold to a Buy and raised his price target to $31, suggesting 28% upside potential. Wall Street isn’t quite as bullish. CGC has a ‘Moderate Buy’ analyst consensus as well as a $42 average price target, implying 73% upside potential. Charlotte’s Web Holdings Inc. (CWBHF)Some analysts believe that the last stock on our list is uniquely positioned to soar as it doesn’t rely on legalization like other players in the space. It already offers CBD products, including capsules and oil, in the U.S. The key here is that these products can also be shipped anywhere in the U.S., legally.Even more exciting for investors, CWBHF is already profitable. On August 14, the company reported second quarter gross profit reached almost $19 million thanks to its products appearing in 1,926 additional retail locations, including CVS Health (CVS) and Kroger (KR), as well as new stock keeping units for gummies and its pets line. While this number is by no means huge, it is significant as the two previous stocks we mentioned have yet to achieve profitability. Charlotte’s Web is also garnering praise for its selection of its new CEO, Deanie Elsner. The former executive at Kraft Heinz (KHC) and Kellogg (K) is widely viewed as a good fit in terms of where the company is now. Based on all of these factors, Piper Jaffray analyst Michael Lavery believes the cannabis stock is well positioned to gain from what is expected to be major growth in the U.S. hemp CBD market. As a result, the one-star analyst initiated coverage with a Buy and set a $25 price target on August 12. Lavery thinks share prices could soar as much as 50% over the next twelve months.The word on the Street is that Charlotte’s Web is a ‘Moderate Buy’. Its $25 average price target indicates 50% upside potential. The Final VerdictThe results are in, with Wall Street betting on Canopy to soar the highest. While analysts still expect significant upside from Aurora and Charlotte's Web, CGC takes the top spot.Find analysts’ favorite stocks with the Top Analysts’ Stocks tool

  • 3 Top Cannabis Stocks to Buy in September
    Motley Fool

    3 Top Cannabis Stocks to Buy in September

    These marijuana stocks look like winners for investors with long-term perspectives.

  • Why Charlotte's Web Shares Fell Today
    Motley Fool

    Why Charlotte's Web Shares Fell Today

    No news was bad news for the hemp CBD market leader.

  • The Booming CBD Market Is the Key for Charlotte’s Web Holdings Stock
    TipRanks

    The Booming CBD Market Is the Key for Charlotte’s Web Holdings Stock

    The cannabis sector has a projected market opportunity topping $200 billion, but the companies that focus on large specific niches such as CBD might provide the best reward to shareholders. Charlotte’s Web Holdings (CWBHF) has the results to prove that focus pays off and the stock is near all-times highs for this reason. Investors waiting for a pullback might not get the opportunity to load up on this hot sector.Q2 Results CWH actually reporting slightly disappointing numbers for Q2. The key being that reported revenues of $25.0 million missed analyst estimates by $1.2 million.Investors can clearly overlook short-term blips as the company moves toward national CB rollouts with CVS Health (CVS) and Kroger (KR), amongst others. Not to mention, the company generated adjusted EBITDA margins of 16% and net income of $2.2 million.Yes, while the big Canadian cannabis LPs lose tons of money building far flung operations across the globe, CWH has already generated a money machine. The company is focused solely on domestic CBD sales via either online sales or distribution partners. The company doesn’t need expensive stores either.For this reason, top line sales growth isn’t nearly as impressive as other market participants, but the gross margins are much higher. Q2 revenues only grew 45% YoY, but CWH is near an inflection point with growth and 7%% gross margins. Analysts forecast quarterly sales to surge to nearly $60 million by next Q1 and to eventually top $100 million by the following December quarter.From the June 2019 quarter to the December 2020 quarter, the CBD specialist will generate 300% quarterly revenue growth. Normal markets would salivate over this type of growth.Reason To Focus The reason to focus on a particular segment of the burgeoning cannabis market is the individual scale and sizes are massive. The domestic CBD market alone is projected to surge from ~$1 billion in 2019 to potentially $7 billion by 2023.(Source: CWB presentation)Too many companies are chasing the full $200 billon market opportunity to mounting losses and cash crunches. CWH has $51.4 million in cash and spent about $10 million in the first half of the year to build inventories. The company doesn’t have massive cash needs outside of building inventories to meet demand.The CBD company already has distribution deals for nearly 8,000 retail locations. CWH has a deal with Kroger for 1,350 stores while the large retailer has double the retail locations leading to easy expansion for CWH once the grocery chain and the market is ready for a full national rollout.TakeawayThe key investor takeaway is that Charlotte’s Web has already become a profit machine by focusing on a sole market niche with a market opportunity topping $7 billion in a few years.The stock has a reasonable market valuation in the $1.8 billion range now with a ’20 revenue target of $300 million. A cannabis or CBD stock trading around 6x forward sales estimates is rather reasonable for the sector, but the volatile sector and complexities of a national rollout of a product where the FDA still has plenty of questions should provide some hiccups that send the stock lower and offer a better entry point for new investors.Visit TipRanks’ Trending Stocks page, and find out what companies Wall Street’s top analysts are looking at now.Disclosure: No position.

  • PR Newswire

    Charlotte's Web Announces Voting Results of Shareholder Meeting

    BOULDER, CO, Aug. 21, 2019 /PRNewswire/ - (TSX: CWEB, OTCQX: CWBHF), Charlotte's Web Holdings, Inc. ("Charlotte's Web" or the "Company"), the market leader in whole-plant hemp CBD extract products is pleased to announce the results from its 2019 annual general and special meeting of shareholders held on August 20, 2019 in New York (the "Meeting").  Each of the matters voted upon at the Meeting is discussed in detail in the Company's Management Information Circular dated July 10, 2019 (the "Circular"), a copy of which is available on the Company's SEDAR profile at www.sedar.com. The total number of votes cast at the Meeting was 55,076,745, representing 56.57% of the total number of votes attached to the outstanding voting shares of the Company. The appointment of MNP LLP as the auditors of the Company to hold office until the close of the next annual meeting of shareholders of the Company.

  • Better CBD Stock: Charlotte's Web vs. CV Sciences
    Motley Fool

    Better CBD Stock: Charlotte's Web vs. CV Sciences

    Which purveyor of high-margin, nonintoxicating cannabis products will earn the largest share of this growing market?

  • Here's My Top Cannabis Stock to Buy in August
    Motley Fool

    Here's My Top Cannabis Stock to Buy in August

    This CBD leader is poised to deliver handsome returns to shareholders.

  • Why Charlotte's Web Stock Slipped Again Today
    Motley Fool

    Why Charlotte's Web Stock Slipped Again Today

    Investors appear to be worried that the company's growth could be stymied by the FDA's sluggishness in establishing CBD regulations.

  • Marijuana Stocks: Catch the Next Hot Pot Stock Before It ‘Jumps’
    InvestorPlace

    Marijuana Stocks: Catch the Next Hot Pot Stock Before It ‘Jumps’

    Among marijuana stocks, very few have achieved profitability. But sooner or later, every company needs to reach that milestone.That sounds obvious, like "Business 101." In fact, it's one of the most basic requirements for a stock to trade on the "Big Board," the New York Stock Exchange (NYSE)… and also for the Nasdaq, for that matter.And yet, in the cannabis industry, Charlotte's Web (OTCMKTS:CWBHF) is one of the few that can deliver positive earnings! That's just one reason I want to put it on your radar today.InvestorPlace - Stock Market News, Stock Advice & Trading TipsCharlotte's Web was one of the original hemp-cannabidiol (CBD) companies, and perhaps the biggest success story of Colorado's legal cannabis boom. * 10 Stocks Under $5 to Buy for Fall CWBHF is also my pick for InvestorPlace's Best Stocks for 2019 contest - but really, it's among the top marijuana stocks for the next three years, at least, and here's why:With news Wednesday that the company's Q2 revenue rang in at $25 million, Charlotte's Web is expecting to post sales of $120-$170 million for the year. (At the midpoint, that puts the stock at a very attractive price-to-sales ratio of just 6X). But next year, analysts are expecting sales of $348 million… and $444 million the year after that.If that sounds lofty, keep in mind that Charlotte's Web CBD will soon be in twice as many stores as it was last year. From a niche product that was mainly found in health stores, you can now buy it at "big box" stores like CVS Health (NYSE:CVS) and, now, Kroger (NYSE:KR).The deal with Kroger, announced on July 31, is big; it adds 1,350 stores (in 22 states) to Charlotte's Web's retail network. The total number of retail locations carrying the company's products stood at 7,817 at the end of the quarter, up 1,926.Demand for hemp-CBD and this particular brand is booming, and to keep up, Charlotte's Web just expanded into the prestigious Colorado Technology Center, strategically located between the cities of Boulder and Denver.With the new location, Charlotte's Web will quadruple its footprint. After all, to make hemp-CBD, you've got to process a lot of hemp. And while operations will begin "early next year," the growth opportunity there will be just beginning.The Colorado Tech Center is better known for its tech startups, and Charlotte's Web is bringing some of that same energy to this expansion. Rather than resorting to CBD extraction techniques that are "decades old," their ambition is to use state-of-the-art technology to maintain what's always been the company's edge: "the highest-quality products."Here's another significant edge: reputation. The truth about the CBD market is that there are a lot of bad players - and those other guys will soon be removed by the coming wave of federal regulation. As I always say in Investment Opportunities, marijuana stocks are one group that needs regulators. And as a legitimate leader of the industry, Charlotte's Web will be the beneficiary.That's the context of the company's eye-catching earnings-per-share (EPS) projections. Already leading the pack with $0.27 per share expected this year, that should increase to $0.74 next year and $1.06 in 2021.The stock is up 65% since I picked it for the Best Stocks contest, even after it stumbled on Wednesday's quarterly report. But given these projections, CWBHF is still a steal as it trades around $20 on the over-the-counter (OTC) markets.As for the major stock exchanges - which open up a whole new world to companies like this - Charlotte's Web is on the right track to meet the NYSE and Nasdaq's earnings requirements for the long term. And I always believe in investing in a great stock early - BEFORE it makes that jump. Marijuana Stocks: Another "Jumper" Stock You Won't Want to MissGiven that it's fully legalized on its federal level, Canada is always a popular place to look for marijuana stocks, too. And one of my picks there just announced that it will "jump" to the Toronto Stock Exchange. (Charlotte's Web did, too, for that matter.)When a company moves to the big leagues, it opens up lots of doors for financing, offerings, and big institutional money. It's like the market's "seal of approval": an elite status with long-term benefits to the share price.In the next six to 12 months, I expect this particular Canadian stock to announce a second uplisting - to a U.S. exchange. That would be even more significant.Business wise, I'd put its extraction operation up against anyone's. At Investment Opportunities, you can get all the details on this and other up-and-coming cannabis stocks in the legalization mega-trend. Timing is EverythingEarly stage investing can be exciting… but also tricky.When a new industry booms - when billions of dollars are up for grabs - you can be sure all kinds of people will rush into the sector and try to get their share.Some of the companies will have smart, hardworking people running the show… great people to invest with. But, let me tell you, some of these folks aren't the kind of people you'd ever want to invite over for dinner… let alone do business with.That's a fact of life in any industry. But this challenge is magnified in a new industry with massive potential - like the legal marijuana industry.This is why it is critical to have a system… a framework for evaluating legal marijuana stocks.A path to profitability is certainly one of the things I look for here. But there's a little more to it than that!So, I created a 5-Factor Analytical Model for evaluating newly public legal marijuana companies to as part of my Cannabis Cash Calendar.I've put my model to the test in recent weeks to uncover my next Cannabis Cash Calendar recommendation… which I just released on Tuesday to my Investment Opportunities readers. But there is still time for you to get in on it, too, as it's still under my buy price!The opportunity in legal weed is much like the opportunity internet stocks offered in 1994… or that bitcoin offered in 2015. It is set to grow so much over the next 10 years that it will turn out to be one of the three biggest investment opportunities of your entire life - no matter when you were born.Click here to learn more and find out how you can get immediate access to my new recommendation.Matthew McCall is the founder and president of Penn Financial Group, an investment advisory firm, as well as the editor of Investment Opportunities and Early Stage Investor. He has dedicated his career to getting investors into the world's biggest, most revolutionary trends BEFORE anyone else. The power of being "first" gave Matt's readers the chance to bank +2,438% in Stamps.com (STMP), +1,523% in Ulta Beauty (ULTA), +1,044% in Tesla (TSLA), +611% in Liquefied Natural Gas Limited (LNGLY), +324% in Bitcoin Services (BTSC), just to name a few. If you're interested in making triple-digit gains from the world's biggest investment trends BEFORE anyone else, click here to learn more about Matt McCall and his investments strategy today. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Stocks Under $5 to Buy for Fall * 5 Stocks to Avoid Amid the Ongoing Trade War * 7 5G Stocks to Buy Now for the Future The post Marijuana Stocks: Catch the Next Hot Pot Stock Before It 'Jumps' appeared first on InvestorPlace.

  • Charlotte's Web Second-Quarter Results: Top and Bottom Lines Head in Different Directions
    Motley Fool

    Charlotte's Web Second-Quarter Results: Top and Bottom Lines Head in Different Directions

    The cannabidiol (CBD) leader returned to solid sequential revenue growth, but its spending soared even more than its sales did.

  • Benzinga

    CBD Maker Charlotte's Web Posts 75% Gross Margins In Q2

    Charlotte’s Web Holdings, Inc. (OTC: CWBHF ) reported 45% year-over-year second-quarter revenue growth Wednesday. Gross margins for the quarter were 75.3%, with $18.8 million in gross profits. The whole-plant ...

  • Why Charlotte's Web Stock Is Sinking Today
    Motley Fool

    Why Charlotte's Web Stock Is Sinking Today

    Shares of this CBD pioneer are falling as a result of Q2 revenue and earnings misses.

  • 3 Reasons to Love Cronos Stock
    InvestorPlace

    3 Reasons to Love Cronos Stock

    The bumpy ride for Cronos (NASDAQ:CRON) stock investors continued this week when the cannabis stock got some more love from Wall Street. On Monday, Piper Jaffray analyst Micael Lavery initiated coverage of Cronos Group stock with an "outperform" rating and $18 price target.Lavery's initiation note was 29 pages long. However, the bull case for Cronos boils down to three main points.Source: ShutterstockInvestorPlace - Stock Market News, Stock Advice & Trading Tips CRON Stock Has a Big BrotherWhile other cannabis producers are out there trying to grow their business organically, Cronos has a perfect benefactor. In December 2018, tobacco giant Altria (NYSE:MO) invested $1.8 billion for a 45% stake in Cronos. In my opinion, the Altria partnership is the single biggest reason to consider CRON stock."We believe its partnership with Altria provides important capital ($1.8 billion cash) and access into 230,000 U.S. retail outlets, as well as regulatory and vapor product expertise," Lavery wrote. * 15 Growth Stocks to Buy for the Long Haul I would add two points to Lavery's case. U.S. (and potentially global) cigarette volumes are seemingly in secular decline. In other words, Altria needs Cronos as much as Cronos needs Altria. Tobacco companies are starving for growth. Cannabis could be a long-term lifeline.Second, Cronos Group stock investors hoping for U.S. cannabis legalization should realize one thing about their investment. They are investing in a tobacco company. As part of the terms of its 45% investment deal, Altria has the rights to take a full ownership stake at some point down the line.In my opinion, whether or not Altria exercises that option hinges on U.S. cannabis legalization. Without access to the U.S. market, Altria may not want to fully acquire Cronos. But if the U.S. ultimately legalizes weed on a federal level, I bet Altria's first move is a Cronos takeover.Progressive CRON stock investors may not like the idea of a tobacco takeover. But if the future of Altria is cannabis, at some point Altria is no longer a tobacco company at all. CBD Provides CRON Access to U.S. MarketAll cannabis stock investors know that U.S. federal marijuana legalization is the golden ticket. In the meantime, cannabidiol (CBD) may be the best way for Canadian producers like Cronos to get their foot in the U.S. door.CBD is a non-psychoactive, cannabis-derived chemical compound that was legalized in the U.S. in December 2018. The caveat is that only CBD produced from hemp, not marijuana, is legal. Lavery is expecting Cronos to use its $1.8 billion in Altria capital to launch a U.S. CBD strategy within the next year. In fact, he is projecting 60% of Cronos' 2020 revenue will come from CBD. Cronos Group's Brand AwarenessThe third big feather in Cronos Group's cap is its recent $300 million buyout of Redwood Holdings, parent company of early CBD brand leader Lord Jones.For millennial investors who are a fan of alternative data, Lavery included a cool statistic on Lord Jones in his note. Lord Jones alone has nearly 80,000 Instagram followers. That's more followers than the leading brands of popular cannabis stocks Tilray (NASDAQ:TLRY), Charlotte's Web Holdings (OTC:CWBHF) and Curaleaf Holdings (OTC:CURLF).It may seem like a trivial statistic, but social media popularity is an important measure of brand popularity. Marketing experts know brands are the key to success in untapped markets like the U.S. If Lord Jones becomes one of the gold standards in U.S. CBD, don't be surprised if Cronos/Altria markets its marijuana under the Lord Jones brand in the event of U.S. legalization. Understanding the Risks of CRON StockThe one thing I always try to include in my stories about cannabis stocks is a note about the risks involved in investing. There are so many uncertainties in the cannabis space right now. As if that weren't enough of a risk, cannabis stock valuations are sky-high, likely including at least some expected value from the U.S. marijuana market.Instead of rehashing points I've repeatedly made, here's Lavery's take:"We see a long runway of growth in the cannabis space, but valuation still has many speculative elements and can be very imprecise, given the early stages of the category and the myriad ways it could evolve," he wrote.Lavery makes some good points about buying CRON stock. However, any cannabis stock is a pure speculation at this time and these valuations. Don't invest any cash you wouldn't be comfortable losing in a worst-case scenario.As of this writing, Wayne Duggan did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 15 Growth Stocks to Buy for the Long Haul * 5 More Cloud Stocks With Plenty of Potential * 5 Clean Energy ETFs to Buy for 2019 The post 3 Reasons to Love Cronos Stock appeared first on InvestorPlace.

  • PR Newswire

    Charlotte's Web Names Russell Hammer as Chief Financial Officer

    BOULDER, CO, Aug. 14, 2019 /PRNewswire/ - (TSX: CWEB, OTCQX: CWBHF), Charlotte's Web Holdings, Inc. ("Charlotte's Web" or the "Company"), the market leader in whole-plant hemp CBD extract products with naturally occurring cannabinoids, including cannabidiol ("CBD"), is pleased to announce that Russell Hammer has joined the Company as Chief Financial Officer, effective tomorrow, August 15, 2019. Mr. Hammer, who has most recently served as an advisor in private equity investments, brings more than 30 years of finance experience in the retail, tourism and technology sectors. With his experience leading multi-billion-dollar multinational companies, he is the latest top-tier executive to join Charlotte's Web as the Company accelerates its growth and evolution into a global consumer packaged goods ("CPG") brand.

  • PR Newswire

    Charlotte's Web Holdings Reports 2019 Q2 Earnings

    Q2 revenue increases 45% YoY to US$25.0 million Adjusted EBITDA of $3.9 million and US$0.02 EPS BOULDER, CO , Aug. 14, 2019 /PRNewswire/ - (TSX:CWEB, OTCQX:CWBHF), Charlotte's Web Holdings, Inc. (" ...

  • Charlotte's Web Announces 137,000 SF Manufacturing and Distribution Expansion to Support Long-Term Growth
    CNW Group

    Charlotte's Web Announces 137,000 SF Manufacturing and Distribution Expansion to Support Long-Term Growth

    BOULDER, CO , Aug. 8, 2019 /CNW/ - Charlotte's Web Holdings, Inc. ("Charlotte's Web" or the "Company") (TSX:CWEB, OTCQX:CWBHF), the market leader in hemp CBD extract products, announces expansion plans underway in 2019  including cultivation, production, distribution and R&D to support its forecasted sales growth. The new location enables the Company to prepare for production, distribution and R&D expansion to meet increasing demand from the consumer and national retailer channels. Charlotte's Web will commence a staged build-out of the facility during Q3-2019 and continuing over a two year period.

  • 2 Best Cannabis Stocks to Buy in August
    Motley Fool

    2 Best Cannabis Stocks to Buy in August

    Auxly Cannabis Group and Charlotte's Web Holdings are poised for serious growth.

  • PR Newswire

    Charlotte's Web Holdings Inc. Issues Q2 Earnings Conference Call Notice

    BOULDER, CO, July 31, 2019 /PRNewswire/ - Charlotte's Web Holdings, Inc. ("Charlotte's Web" or the "Company") (TSX:CWEB, OTCQX:CWBHF), the market leader in hemp CBD extract products, will issue its 2019 second quarter results on August 14 before the open of trading on the Toronto Stock Exchange.  A conference call to discuss the results has been scheduled for the same day at 10:00 a.m. Eastern Time. To participate in the call, please dial 1-647-427-7450 or 1-888-231-8191 approximately 10 minutes before the conference call and provide conference ID 8685806.  A recording of the call will be available through August 21, 2019. To listen to the rebroadcast please dial 1-416-849-0833 and provide the same conference ID.

  • Charlotte’s Web Getting More Aggressive in the U.S. CBD Market, But Questions Remain
    TipRanks

    Charlotte’s Web Getting More Aggressive in the U.S. CBD Market, But Questions Remain

    Charlotte's Web (CWBHF) recently announced it added grocery giant Kroger (KR) to its growing list of retail outlets it will sell CBD products through. That will add another 1,350 outlets to its already impressive retail distributor base.Deanie Elsner, CEO of Charlotte's Web, said this about the deal:"Since its founding, Charlotte's Web has been on a mission to make CBD products available for as many people as possible. This distribution reach through Kroger's market leading network of grocery stores is an enormous contributor to our mission..."With Brightfield Group projecting CBD sales to soare to $22 billion by 2022, Charlotte's Web is positioning itself to take a nice chunk of that revenue.The biggest question concerning CBD to me is whether or not the estimated growth in sales is too optimistic, and expectations need to be lowered.CBD growth expectationsThe first thing to consider in regard to CBD growth expectations is if the $22 billion revenue projection is overly optimistic, within the short time frame it is expected to reach that level, which less than 30 months.Also important in relationship to Charlotte's Web is not only what percentage of that revenue it'll grab, but if it will be able to brand itself via a variety of CBD products to allow it to stand out in the minds of consumers. It's one thing for CBD sales to soar, it's another thing for a company to separate itself in the minds of consumers against their competitors. CBD could easily, in general, become a commodity market that competes primarily on price.That's why I remind investors continually that CBD should be considered similar to the vitamin and supplement markets. It's going to cater in some degree to the same type of customers, and since government entities like the FDA don't allow CBD products to be touted as cures or treatments for diseases, it makes it harder to pull away from the pack.That's why Charlotte's Web need to offer CBD products to the market based upon what consumers determine the value of specific products are to their health. That's how the vitamin and supplement markets work.Beyond compelling packaging, Charlotte's Web will have to find ways to convince consumers some of their CBD products are worth a higher price point.One way it is doing that is in the types of partners it will distribute through, such as Kroger. Even so, some of its competitors have done the same, so in going head-to-head with its major competitors, investors will need to identify how the company will differentiate from the plethora of products offered by a growing number of companies.Those best able to brand should be able to not only generate the most revenue, but also wider margins and stronger earnings, because consumers are willing to pay a premium for their products.Charlotte's Web's distribution reachWith the addition of Kroge to its distribution network, Charlotte's Web now has 5 major retailers it's distributing through, along with a number of specialty retailers. It now has a presence in over 8,000 U.S. locations it can distribute its CBD products through.In the Kroger universe, it will not only sell through the main grocery store bearing that name, but also via Dillons, Fred Meyer, King Soopers, Fry's, Mariano's, Pick 'n Save, QFC and Smith's, aka the Kroger Family of Stores.What's important isn't the number of distribution outlets is has, but the level it can leverage those locations to generate a profit. It also has yet to prove it will be able to sustainably grow revenue and earnings at the many stores it now will sell through.While the company claims it is "the most sought-after CBD brand," it's far too premature to make that claim. We're just in the very early stages of the CBD market, and it has yet to be determined who the long-term winners will be.ConclusionCharlotte's Web is positioned well to back up that assertion, but I believe the key will be which companies brand the best and are able to, for the most part, compete outside of the commodity CBD market.What I mean by that is in any retail market there will be loss leaders and low priced products to get consumers to try them out, with the purpose of getting them interested in trying out premium products.Word of mouth concerning the effect specific products have on various health conditions will be a big part of CBD winners, and that will have to come from feedback from consumers because of the restrictions by the FDA in the U.S. concerning making claims about healing and curing conditions.I believe there will be another part of the CBD market which after research and confirmed results, will open up a potential market similar to pharaceuticals. GW Pharmaceuticals and Epidiolex are the obvious example of that.If Charlotte's Web ever is able to offer those type of CBD products that are considered legitimate treatments by the FDA, it would have the potential to generate billions over time.But as the company stands today, it does have a strong foothold in the retail market, and if it is able to successfully differentiate itself from competitors, it has a strong growth trajectory ahead of it, even if the CBD market doesn't reach $22 billion in a couple of years.If it doesn't drop the ball, it should reward shareholders over the next few years at least.Charlotte's Web has a small, but vocal camp of bullish analysts with positive expectations for the stock. Out of the 3 analysts polled by TipRanks, all 3 rate the stock a Buy. With a return potential of 27%, the stock's 12-month consensus target price stands at C$29.50. (See Charlotte's Web's price targets and analyst ratings on TipRanks)